Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 290-296

  Stanisavljevic, Natasa S ^a   Marisavljevic, D Z ^a  

^a Clinical and Hospital Center Bezanijska Kosa   (Serbia)

Author keywords

Body composition; Body weight; Dose intensity; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY WATER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LEAN BODY WEIGHT; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; WEIGHT CHANGE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; BODY HEIGHT; BODY WEIGHT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ELECTRIC IMPEDANCE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; VINCRISTINE; WEIGHT GAIN; WEIGHT LOSS; YOUNG ADULT;

EID: 77954393924     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DeWys D, Begg C, Lavin T et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491-496.
2. Skipworth R, Stewart G, Dejong C, Preston T, Fearon K. Pathophysiology of cancer cachexia: Much more than host-tumour interaction? Clin Nutr 2007; 26: 667-676. (Pubitemid 350107710)
3. Cohen SH, Gartenhaus W, Sawitsky A el al. Compartmental body composition of cancer patients by measurements of total body nitrogen, potassium, and water. Metabolism 1981; 30: 222-229.
4. Warnold I, Lundholm K, Schersten T. Energy balance and body composition in cancer patients. Cancer Res 1978; 38: 1801-1807. (Pubitemid 8349732)
5. Watson WS, Sammon AM. Body composition in cachexia resulting from malignant and non-malignant diseases. Cancer 1980; 46: 2041-2046.
6. Shizgal H. Body composition of patients with malnutrition and cancer. Summary of methods and assessment. Cancer 1985; 55: 250-253.
7. McMillan D, Watson W, Preston T, McArdle C. Lean body mass changes in cancer patients with weight loss. Clin Nutr 2000; 19: 403-406.
8. Kyle U, Bosaeus I, De Lorenzo A et al. Bioelectrical impedance analysis - part I: review of principles and methods. Clin Nutr 2004; 23: 1226-1243.
9. Kyle U, Bosaeus I, De Lorenzo A et al. Bioelectrical impedance analysis - part II: utilization in clinical practice. Clin Nutr 2004; 23: 1430-1453.
10. Conlisk E, Hass J, Martinez E et al. Predicting body composition from anthropometry and bioimpedance. Am J Clin Nutr 1992; 55: 1051-1059.
11. Durnin A, Rahaman M. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 1967; 21: 681-690.
12. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's lymphoma Prognostic Factor Project. N Engl J Med 1993; 329: 987-994.
13. 2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging 2007; 27: 135-137. (Pubitemid 46605404)
14. Baker S, Verweij J, Rowinsky E et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-1888.
15. Aslani A, Smith R, Allen B, Pavlakis N, Levi J. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88: 796-803. (Pubitemid 30091099)
16. Morgan D, Bray K. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Gut 2003; 52: 1391-1392.
17. Prado C, Baracos V, McCargar L et al. Body composition as an independent determinant of 5-fluorouracil- based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264-3268. (Pubitemid 46944911)
18. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288. (Pubitemid 15202705)
19. Foltz A. Weight gain among stage II breast cancer patients: a study of five factors. Oncol Nurs Forum 1985; 12: 21-26.
20. Demark-Wahnefried W, Winer E, Rimer B. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 1993; 11: 1418-1429. (Pubitemid 23199148)
21. Freedman R, Aziz N, Albanes D et al. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. JCEM 2004; 89: 2248-2253. (Pubitemid 38619860)
22. Muszynska-Roslan K, Konstantynowicz J, Krawczuk-Rybak M. Body composition and bone mass in survivors of childhood cancer. Pediatr Blood Cancer 2007; 48: 200-204. (Pubitemid 44958278)
23. Warner J, Evans W, Webb D, Gregory J. Pitfalls in the assessment ofbody composition in survivors of acute lymphoblastic leukaemia. Arch Dis Chil 2004; 89: 64-68. (Pubitemid 38122016)
24. Epelbaum R, Haim N, Ben-Shahar M et al. Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988; 24: 533-538. (Pubitemid 19052765)
25. Lepage E, Gisselbrecht C, Haioun C et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol: The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993; 4: 651-656.
26. Lee KW, Kim DY, Yun T et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003; 98: 2651-2656. (Pubitemid 37509529)
27. Hagberg H, Bjorkholm M, Glielius B et al. CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: A randomized trial. Eur J Cancer Clin Oncol 1985; 21: 175-179. (Pubitemid 15169689)
28. Gams RA, Rainey M, Dandy M et al. Phase III study of BCOP vs CHOP in unfavorable categories of malignant lymphoma: A Southeastern Cancer Study Group trial. J Clin Oncol 1985; 3: 1188-1195. (Pubitemid 15226523)
29. Meyer R, Hryniuk W, Goodyear M. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 339-347.